{
    "clinical_study": {
        "@rank": "30061", 
        "acronym": "Rainier", 
        "arm_group": [
            {
                "arm_group_label": "OGX-427", 
                "arm_group_type": "Experimental", 
                "description": "Three loading doses of OGX-427 at 600mg IV will be administered Days -9 to -1. Following the loading dose period, OGX-427 will be administered at 600mg IV weekly Days 1, 8, 15, and 22 of each 28 day cycle during the Treatment Phase."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Three loading doses of placebo will be administered Days -9 to -1. Following the loading dose period, placebo will be administered weekly Days 1, 8, 15, and 22 of each 28 day cycle."
            }
        ], 
        "brief_summary": {
            "textblock": "To compare the overall survival in patients with previously untreated metastatic pancreatic\n      cancer receiving:\n\n      gemcitabine/nab-paclitaxel plus OGX-427 or gemcitabine/nab-paclitaxel plus placebo"
        }, 
        "brief_title": "Phase II Trial Of Gemcitabine Plus Nab-Paclitaxel +/- OGX-427 In Patients With Metastatic Pancreatic Cancer", 
        "completion_date": {
            "#text": "May 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Pancreatic Cancer", 
        "condition_browse": {
            "mesh_term": "Pancreatic Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Histologically- or cytologically confirmed pancreatic adenocarcinoma\n\n          2. Stage IV disease (measurable disease NOT required)\n\n          3. Eastern Cooperative Oncology Group (ECOG) performance score of 0-1\n\n          4. At least 18 years of age\n\n          5. Female patients who are not of child-bearing potential, and fertile female patients\n             of child-bearing potential who agree to use adequate contraceptive measures, who are\n             not breastfeeding, and who have a negative serum or urine pregnancy test within 72\n             hours prior to start of randomization.\n\n          6. Fertile male patients willing to use adequate contraceptive measures.\n\n          7. Adequate bone marrow function:\n\n               -  Absolute neutrophil count (ANC) \u2265 1500/uL\n\n               -  platelet count \u2265 100,000/uL\n\n               -  hemoglobin \u2265 9.0 g/dL\n\n          8. Adequate hepatic function:\n\n               -  Total bilirubin \u2264 1.5 X ULN\n\n               -  Aspartate amino transferase (AST) (SGOT) \u2264 3.0 X ULN\n\n               -  Alanine aminotransferase (ALT) (SGPT) \u2264 3.0 X ULN\n\n          9. Adequate renal function (defined as serum creatinine \u2264 1.5 X ULN)\n\n         10. Ability to understand the nature of this study protocol, comply with study and/or\n             follow-up procedures, and give written informed consent\n\n         11. Willingness and ability to comply with scheduled visits, treatment plans, laboratory\n             tests, and other study procedures.\n\n        Exclusion Criteria:\n\n          1. Any prior systemic or investigational therapy for metastatic pancreatic cancer.\n             Systemic therapy administered alone or in combination with radiation in the adjuvant\n             or neoadjuvant setting is permissible as long as it was completed > 6 months prior to\n             the time of study randomization.\n\n          2. History of other diseases, metabolic dysfunction, physical examination findings, or\n             clinical laboratory findings giving reasonable suspicion of a disease or condition\n             that, in the opinion of the investigator, renders the subject at high risk from\n             treatment complications or might affect the interpretation of the results of the\n             study.\n\n          3. Presence of known central nervous system or brain metastases.\n\n          4. Known human immunodeficiency virus (HIV) infection.\n\n          5. Active second invasive malignancy (except non-melanomatous skin cancer), defined as\n             any malignancy with current need for cancer therapy or high possibility (>30%) of\n             recurrence during the study.\n\n          6. Patients receiving warfarin.  However, therapeutic anticoagulation with Low Molecular\n             Weight Heparin (LMWH)is allowed.\n\n          7. Clinically significant cardiac disease (e.g. congestive heart failure, symptomatic\n             coronary artery disease, and cardiac arrhythmias not well controlled with medication)\n             or myocardial infarction within the last 6 months.\n\n          8. Current sensory neuropathy > Grade 1.\n\n          9. Major surgery within 4 weeks of the start of study treatment (defined as those\n             surgeries that require general anesthesia.  Insertion of a vascular access device is\n             NOT considered major surgery.).  Patients must have recovered from the side effects\n             of any major surgery prior to randomization."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "132", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 29, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01844817", 
            "org_study_id": "SCRI GI 184"
        }, 
        "intervention": [
            {
                "arm_group_label": "OGX-427", 
                "description": "Three separate administrations of OGX-427 will be given during the 9-day Loading Dose Period.  Following the Loading Dose Period, patients will receive 600mg OGX-427 prior to the administration of nab-paclitaxel (125mg/m2 IV)and gemcitabine (1000mg/m2 IV)administration on Day 1, 8, and 15 of each cycle.  OGX-427 will also be administered on Day 22 during each cycle (i.e., weekly).  Patients will continue 28 day treatment cycles until disease progression or until other reasons for discontinuation from treatment.", 
                "intervention_name": "OGX-427", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Three separate administrations of Placebo will be given during the 9-day Loading Dose Period.  Following the Loading Dose Period, patients will receive placebo prior to the administration of nab-paclitaxel (125mg/m2 IV)and gemcitabine (1000mg/m2 IV)administration on Day 1, 8, and 15 of each cycle.  Placebo will also be administered on Day 22 during each cycle (i.e., weekly).  Patients will continue 28 day treatment cycles until disease progression or until other reasons for discontinuation from treatment.", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Gemcitabine", 
                "Paclitaxel"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "untreated", 
            "metastatic", 
            "OGX-427"
        ], 
        "lastchanged_date": "April 22, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "San Francisco", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94115"
                    }, 
                    "name": "University of California-San Francisco"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ft. Myers", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33916"
                    }, 
                    "name": "Florida Cancer Specialists-South"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Orlando", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32804"
                    }, 
                    "name": "Florida Hospital Cancer Insitute"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St. Petersburg", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33705"
                    }, 
                    "name": "Florida Cancer Specialists-North"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Harvey", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60426"
                    }, 
                    "name": "Ingalls Cancer Research Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cincinnati", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "45242"
                    }, 
                    "name": "Oncology Hematology Care, Inc."
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Columbia", 
                        "country": "United States", 
                        "state": "South Carolina", 
                        "zip": "29210"
                    }, 
                    "name": "South Carolina Oncology Associates"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chattanooga", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37404"
                    }, 
                    "name": "Tennessee Oncology - Chattanooga"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "AskSARAH@scresearch.net", 
                    "last_name": "AskSARAH"
                }, 
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37203"
                    }, 
                    "name": "Tennessee Oncology, PLLC"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Fort Worth", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "76104"
                    }, 
                    "name": "The Center for Cancer and Blood Disorders"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Richmond", 
                        "country": "United States", 
                        "state": "Virginia", 
                        "zip": "23230"
                    }, 
                    "name": "Virginia Cancer Institute"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Double-Blinded, Placebo-Controlled Phase II Trial Of Gemcitabine Plus Nab-Paclitaxel Combined With OGX-427 Or Placebo In Patients With Metastatic Pancreatic Cancer (The Rainier Trial)", 
        "other_outcome": {
            "description": "To evaluate the effect of treatment with OGX-427 on serum HSP-27 levels", 
            "measure": "Serum Levels of Hsp27", 
            "safety_issue": "No", 
            "time_frame": "Every cycle (4 weeks)"
        }, 
        "overall_contact": {
            "email": "asksarah@scresearch.net", 
            "last_name": "Sarah Cannon Research Institute (SCRI)", 
            "phone": "877-691-7274"
        }, 
        "overall_official": {
            "affiliation": "SCRI", 
            "last_name": "Johanna Bendell, M.D.", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "February 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To compare the overall survival in patients with previously untreated metastatic pancreatic cancer receiving gemcitabine/nab-paclitaxel plus OGX-427 versus gemcitabine/nab-paclitaxel plus placebo)", 
            "measure": "Overall Survival", 
            "safety_issue": "No", 
            "time_frame": "Time from randomization until death"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01844817"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "To compare progression-free survival in each arm", 
                "measure": "Progression-Free Survival", 
                "safety_issue": "No", 
                "time_frame": "Every 8 weeks"
            }, 
            {
                "description": "To compare objective response rate for each treatment arm", 
                "measure": "Objective Response Rate", 
                "safety_issue": "No", 
                "time_frame": "Every 8 weeks"
            }, 
            {
                "description": "To compare CA19-9 levels between treatment arms of patients with elevated levels at baseline", 
                "measure": "CA19-9 Levels", 
                "safety_issue": "No", 
                "time_frame": "Every cycle (4 weeks)"
            }, 
            {
                "description": "To compare the safety/tolerability of gemcitabine/nab-paclitaxel/placebo with gemcitabine/nab-paclitaxel/OGX-427.  Toxicities will be assessed using Common Terminology Criteria for Adverse Events v4.0", 
                "measure": "Safety of the regimen", 
                "safety_issue": "Yes", 
                "time_frame": "Continuous review"
            }
        ], 
        "source": "SCRI Development Innovations, LLC", 
        "sponsors": {
            "collaborator": {
                "agency": "OncoGenex Pharmaceuticals", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "SCRI Development Innovations, LLC", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}